Schizophrenia News and Research

Latest Schizophrenia News and Research

Cortex third quarter net loss increases to $1,175,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $1,175,000, or $0.01 per share, for the quarter ended September 30, 2011, compared with a net loss of approximately $528,000, or $0.01 per share, for the corresponding prior year quarter.

14 Nov 2011

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Link between heavy methamphetamine use and schizophrenia

In the first worldwide study of its kind, scientists from Toronto's Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Chemical breakthrough could simplify drug development process

A new chemical process developed by a team of Harvard researchers greatly increases the utility of Positron Emission Tomography (PET) in creating real-time 3-D images of chemical process occurring inside the human body.

5 Nov 2011

Toxoplasma gondii directly affects production of dopamine in brain

A research group from the University of Leeds has shown that infection by the brain parasite Toxoplasma gondii, found in 10-20 per cent of the UK's population, directly affects the production of dopamine, a key chemical messenger in the brain.

5 Nov 2011

Study: People with schizophrenia have weakened sense of body ownership

A study using a procedure called the rubber hand illusion has found striking new evidence that people experiencing schizophrenia have a weakened sense of body ownership and has produced the first case of a spontaneous, out-of-body experience in the laboratory.

1 Nov 2011

PPRT publishes study that evaluates pharmacist provision of clozapine

According to a study which evaluated alternative models for the delivery of clozapine services, published by the Pharmacy Practice Research Trust (PPRT), there is scope to review the team configurations needed to deliver community services in a cost-effective manner and to provide opportunities for improving the services provided to patients.

31 Oct 2011

Researchers identify FMRP protein as key player in RNA editing

The most common form of heritable cognitive impairment is Fragile X Syndrome, caused by mutation or malfunction of the FMR1 gene. Loss of FMR1 function is also the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others.

31 Oct 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome

Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark, announced today that the U.S. Food and Drug Administration (FDA) has approved ONFI as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients two years and older.

24 Oct 2011

VTT research exploits metabolics

VTT is seeking to create new development paths towards a healthier life. New opportunities created by metabolics in the fields of diagnostics, medical development, industrial biotechnology and environmental technology have been a part of VTT research for almost 10 years.

22 Oct 2011

Critical migrating neurons in the human brain decline during infancy

José Manuel García Verdugo, full professor of Cell Biology at University of Valencia, together with a University of California research team, has participated in the discovery of new pathways of neurons migrating from lateral ventricles to the prefrontal cortex. The work done in chidren at early ages reveals a new cell pathway which may increase the amount of neurons in regions important for cognitive tasks, emotional processes and spatial perception.

22 Oct 2011

Neuroscientists discover normal brain communication in people with AgCC

Like a bridge that spans a river to connect two major metropolises, the corpus callosum is the main conduit for information flowing between the left and right hemispheres of our brains. Now, neuroscientists at the California Institute of Technology have found that people who are born without that link-a condition called agenesis of the corpus callosum, or AgCC-still show remarkably normal communication across the gap between the two halves of their brains.

20 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

Common link between Type 2 diabetes and autism

A review of the genetic and biochemical abnormalities associated with autism reveals a possible link between the widely diagnosed neurological disorder and Type 2 diabetes, another medical disorder on the rise in recent decades.

20 Oct 2011

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011